{"id":619,"date":"2017-11-28T11:19:19","date_gmt":"2017-11-28T09:19:19","guid":{"rendered":"http:\/\/blogs.uct.ac.za\/cancerphd\/?p=619"},"modified":"2017-11-30T15:19:27","modified_gmt":"2017-11-30T13:19:27","slug":"del-16-in-acute-myeloid-leukaemia","status":"publish","type":"post","link":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/","title":{"rendered":"del 16 in Acute Myeloid Leukaemia"},"content":{"rendered":"

del 16 in Acute Myeloid Leukaemia (AML) in children: Are the Clinical Implications for Management the Same as for Other Good Risk Cytogenetic\u00a0Myeloid Leukaemias in Children?<\/strong><\/span><\/h1>\n

By Marc Hendricks<\/em><\/p>\n

Recently del 16 has been described in AML in children and adults. According to current guidelines risk stratification for paediatric myeloid leukaemias is based on cytogenetic profiling. Patients with leukaemia with good risk cytogenetic profiles are treated with intensive chemotherapy alone and are not considered candidates for transplantation in first remission. These karyotypes include t(8;21), inv(16), t(16;16) previously described in the association with historical French-American-British M4Eo and t(15;17) in acute promyelocytic leukaemia (APL) along with the other known microvariants.<\/p>\n

With the description of the del 16 questions have been raised about whether or not this specific genetic abnormality constitutes a newly discovered good risk variant and whether the same treatment algorithm can be followed as for the other favourable cytogenetic group. The distinction is an important one because it speaks to the need for transplantation to consolidate a remission following intensive chemotherapy: in other words, can transplant be avoided or should children with del16 rather be assigned to a standard risk group and should practitioners then be looking for HLA identical donors to proceed to transplant?<\/p>\n

Considering the small number of reported cases there is, as yet, no clear indication that the deletion is interchangeable (as it refers to risk) with inv16 and t(16;16). The source links<\/span> provided highlight the recent descriptions and the controversial question that it has raised for the management of myeloid leukaemia in children.<\/p>\n

Source\u00a0links:\u00a0Arthur and Bloomfield (1983)<\/a>,\u00a0\u00a0Rogers et al. (2017)<\/a>,\u00a0Silva et al. (2004)<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

del 16 in Acute Myeloid Leukaemia (AML) in children: Are the Clinical Implications for Management the Same as for Other Good Risk Cytogenetic\u00a0Myeloid Leukaemias in Children? By Marc Hendricks Recently … Continue reading del 16 in Acute Myeloid Leukaemia<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\ndel 16 in Acute Myeloid Leukaemia - Postgraduate Cancer Research Initiative (CRI) blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"del 16 in Acute Myeloid Leukaemia - Postgraduate Cancer Research Initiative (CRI) blog\" \/>\n<meta property=\"og:description\" content=\"del 16 in Acute Myeloid Leukaemia (AML) in children: Are the Clinical Implications for Management the Same as for Other Good Risk Cytogenetic\u00a0Myeloid Leukaemias in Children? By Marc Hendricks Recently … Continue reading del 16 in Acute Myeloid Leukaemia →\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Postgraduate Cancer Research Initiative (CRI) blog\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-28T09:19:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-11-30T13:19:27+00:00\" \/>\n<meta name=\"author\" content=\"Harris\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Harris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/\",\"url\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/\",\"name\":\"del 16 in Acute Myeloid Leukaemia - Postgraduate Cancer Research Initiative (CRI) blog\",\"isPartOf\":{\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/#website\"},\"datePublished\":\"2017-11-28T09:19:19+00:00\",\"dateModified\":\"2017-11-30T13:19:27+00:00\",\"author\":{\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/#\/schema\/person\/e54778316be13b56bdf62cbf11476ba8\"},\"breadcrumb\":{\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"del 16 in Acute Myeloid Leukaemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/#website\",\"url\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/\",\"name\":\"Postgraduate Cancer Research Initiative (CRI) blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/#\/schema\/person\/e54778316be13b56bdf62cbf11476ba8\",\"name\":\"Harris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8b2435f300e40e8f28f1f28185bb4e6c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8b2435f300e40e8f28f1f28185bb4e6c?s=96&d=mm&r=g\",\"caption\":\"Harris\"},\"url\":\"https:\/\/blogs.uct.ac.za\/cancerphd\/author\/onydav003\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"del 16 in Acute Myeloid Leukaemia - Postgraduate Cancer Research Initiative (CRI) blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/","og_locale":"en_GB","og_type":"article","og_title":"del 16 in Acute Myeloid Leukaemia - Postgraduate Cancer Research Initiative (CRI) blog","og_description":"del 16 in Acute Myeloid Leukaemia (AML) in children: Are the Clinical Implications for Management the Same as for Other Good Risk Cytogenetic\u00a0Myeloid Leukaemias in Children? By Marc Hendricks Recently … Continue reading del 16 in Acute Myeloid Leukaemia →","og_url":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/","og_site_name":"Postgraduate Cancer Research Initiative (CRI) blog","article_published_time":"2017-11-28T09:19:19+00:00","article_modified_time":"2017-11-30T13:19:27+00:00","author":"Harris","twitter_misc":{"Written by":"Harris","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/","url":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/","name":"del 16 in Acute Myeloid Leukaemia - Postgraduate Cancer Research Initiative (CRI) blog","isPartOf":{"@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/#website"},"datePublished":"2017-11-28T09:19:19+00:00","dateModified":"2017-11-30T13:19:27+00:00","author":{"@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/#\/schema\/person\/e54778316be13b56bdf62cbf11476ba8"},"breadcrumb":{"@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/2017\/11\/del-16-in-acute-myeloid-leukaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.uct.ac.za\/cancerphd\/"},{"@type":"ListItem","position":2,"name":"del 16 in Acute Myeloid Leukaemia"}]},{"@type":"WebSite","@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/#website","url":"https:\/\/blogs.uct.ac.za\/cancerphd\/","name":"Postgraduate Cancer Research Initiative (CRI) blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.uct.ac.za\/cancerphd\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/#\/schema\/person\/e54778316be13b56bdf62cbf11476ba8","name":"Harris","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/blogs.uct.ac.za\/cancerphd\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8b2435f300e40e8f28f1f28185bb4e6c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8b2435f300e40e8f28f1f28185bb4e6c?s=96&d=mm&r=g","caption":"Harris"},"url":"https:\/\/blogs.uct.ac.za\/cancerphd\/author\/onydav003\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/posts\/619"}],"collection":[{"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/comments?post=619"}],"version-history":[{"count":2,"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/posts\/619\/revisions"}],"predecessor-version":[{"id":623,"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/posts\/619\/revisions\/623"}],"wp:attachment":[{"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/media?parent=619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/categories?post=619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.uct.ac.za\/cancerphd\/wp-json\/wp\/v2\/tags?post=619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}